New tests of blood and spinal fluid can show how far Alzheimer's has progressed and how fast a patient's memory will decline.

has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for its investigational drug troculeucel ...

The Fast Track designation accelerates troculeucel’s path to U.S. FDA submission for the treatment of patients with moderate Alzheimer’s disease. NKGen will benefit from increased FDA interactions, ...